LIVIVO - Search results -

Search results

Result 1 - 10 of total 37

Search options

Article ; Online: Cancer du sein triple négatif exprimant le récepteur aux androgènes : de la biologie à la thérapeutique.

Grellety, Thomas

2020 Volume 107, Issue 4, Page(s) 506–516

Abstract: A subgroup of androgen receptor-expressing tumors represents approximately 30 % of all triple negative tumors. The androgen receptor and its signaling pathways have a central biological role in this tumor entity. These triple negative androgen receptor- ... ...

Title translation	Androgen receptor-positive triple negative breast cancer: From biology to therapy.
Abstract	A subgroup of androgen receptor-expressing tumors represents approximately 30 % of all triple negative tumors. The androgen receptor and its signaling pathways have a central biological role in this tumor entity. These triple negative androgen receptor-positive tumors occur in older patients and do not appear to have a better prognosis compared to other triple negative tumors. In addition to androgen receptor-expression, these tumors are genomically characterized by a high frequency of PIK3CA activating mutation. Three clinical trials reported efficacy data for anti-androgens (bicalutamide, abiraterone acetate and enzalutamide) based on strong preclinical rationale. These trials report clinical benefit rates in about one in five patients. These encouraging but still limited results make a case for the identification of predictive response factors and therapeutic combinations to improve response rates. This review will provide an update on the biological and clinical knowledge of this tumoral subgroup that opens the way to non-cytotoxic anti-androgen therapies.
MeSH term(s)	Abiraterone Acetate/therapeutic use ; Age Factors ; Aged ; Androgen Antagonists/therapeutic use ; Anilides/therapeutic use ; Class I Phosphatidylinositol 3-Kinases/genetics ; Clinical Trials as Topic ; Drug Screening Assays, Antitumor ; Female ; Forecasting ; Humans ; Mutation ; Nitriles/therapeutic use ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Prognosis ; Rare Diseases/drug therapy ; Rare Diseases/metabolism ; Receptors, Androgen/metabolism ; Signal Transduction ; Tosyl Compounds/therapeutic use ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/metabolism
Chemical Substances	AR protein, human ; Androgen Antagonists ; Anilides ; Nitriles ; Receptors, Androgen ; Tosyl Compounds ; Phenylthiohydantoin (2010-15-3) ; enzalutamide (93T0T9GKNU) ; bicalutamide (A0Z3NAU9DP) ; Class I Phosphatidylinositol 3-Kinases (EC 2.7.1.137) ; PIK3CA protein, human (EC 2.7.1.137) ; Abiraterone Acetate (EM5OCB9YJ6)
Language	French
Publishing date	2020-03-04
Publishing country	France
Document type	Journal Article ; Review
ZDB-ID	213270-9
ISSN	1769-6917 ; 0007-4551
ISSN (online)	1769-6917
ISSN	0007-4551
DOI	10.1016/j.bulcan.2019.12.012
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Nouvelles AMM : trastuzumab-deruxtecan – cancer du sein métastatique HER2-faible.

Gorgeu, Violaine / Grellety, Thomas

Bulletin du cancer

2023 Volume 110, Issue 6, Page(s) 597–598

Title translation	New drugs approval: Trastuzumab-deruxtecan - HER2-low metastatic breast cancer.
MeSH term(s)	Humans ; Female ; Breast Neoplasms/drug therapy ; Trastuzumab/therapeutic use ; Camptothecin/therapeutic use ; Immunoconjugates ; Receptor, ErbB-2
Chemical Substances	Trastuzumab (P188ANX8CK) ; Camptothecin (XT3Z54Z28A) ; Immunoconjugates ; Receptor, ErbB-2 (EC 2.7.10.1)
Language	French
Publishing date	2023-04-10
Publishing country	France
Document type	Letter
ZDB-ID	213270-9
ISSN	1769-6917 ; 0007-4551
ISSN (online)	1769-6917
ISSN	0007-4551
DOI	10.1016/j.bulcan.2023.03.023
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Stratégies pour la prise en charge des cancers du sein métastatiques récepteurs hormonaux positifs hormonorésistants.

Grellety, Thomas / Hajjaji, Nawale / Petit, Thierry / Bailleux, Caroline

Bulletin du cancer

2022

Abstract: HR+ breast cancers are defined by the prominence of signaling pathways dependent on the estrogen receptor. Endocrine therapy is the standard treatment for these advanced diseases. Resistance to these treatments, called hormone resistance, appears ... ...

Title translation	Therapeutic strategies for the treatment of endocrine resistant hormone receptor positive advanced breast cancer.
Abstract	HR+ breast cancers are defined by the prominence of signaling pathways dependent on the estrogen receptor. Endocrine therapy is the standard treatment for these advanced diseases. Resistance to these treatments, called hormone resistance, appears invariably with biological mechanisms that have led to the development of therapeutic opportunities. An exhaustive literature review was carried out concerning the biology of the hormone resistance pathways, the therapeutic options before the era of CDK4/6 inhibitors, the rise of CDK4/6 inhibitors and the therapeutic prospects in a situation of hormone resistance. Various biological abnormalities have been identified in the mechanisms of hormone resistance such as changes in the estrogen receptor, mutations in the ESR1 gene, aberrant activation of the PI3K pathway or cell cycle deregulations. Historical strategies for circumventing this hormone resistance have been based on hormonal manipulation, on the development of new endocrine therapy such as fulvestrant (selective estrogen receptor inhibitor, SERD), on combinations of treatments such as everolimus, a mTOR inhibitor. This strategy combining endocrine therapy and targeted therapy has led to the development of combinations with CDK4/6 inhibitors which have now become a standard treatment in the hormone resistance phase. The future of this therapeutic era remains to be written with new combinations of hormone therapy and targeted therapy such as PI3K inhibitors or even with the positioning of new SERDs in clinical development.
Language	French
Publishing date	2022-10-25
Publishing country	France
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	213270-9
ISSN	1769-6917 ; 0007-4551
ISSN (online)	1769-6917
ISSN	0007-4551
DOI	10.1016/j.bulcan.2022.09.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.

Meynard, Lucie / Grellety, Thomas

The breast journal

2019 Volume 26, Issue 2, Page(s) 255–257

Abstract: A 59-year-old woman presented with a bone-only metastatic luminal breast cancer. She received first-line treatment with aromatase inhibitors associated with a cyclin-dependent kinase (CDK) 4/6 inhibitor, ribociclib. She developed Grade 3 elevated ... ...

Abstract	A 59-year-old woman presented with a bone-only metastatic luminal breast cancer. She received first-line treatment with aromatase inhibitors associated with a cyclin-dependent kinase (CDK) 4/6 inhibitor, ribociclib. She developed Grade 3 elevated transaminases leading us to interrupt ribociclib permanently. Specific toxicity of the CDK 4/6 inhibitor ribociclib was retained. Once transaminase levels normalized, the patient initiated another CDK4/6 inhibitor, palbociclib, using an escalating dose without reappearance of hepatic injury. This case suggests the possibility of rechallenge after hepatic toxicity with a different CDK 4/6 inhibitor using dose escalation and careful monitoring.
MeSH term(s)	Alanine Transaminase/blood ; Aminopyridines/adverse effects ; Aromatase Inhibitors/therapeutic use ; Aspartate Aminotransferases/blood ; Bone Neoplasms/drug therapy ; Bone Neoplasms/secondary ; Breast Neoplasms/pathology ; Carcinoma, Lobular/drug therapy ; Carcinoma, Lobular/secondary ; Chemical and Drug Induced Liver Injury/blood ; Chemical and Drug Induced Liver Injury/etiology ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Cyclin-Dependent Kinase 6/antagonists & inhibitors ; Drug Substitution ; Drug Therapy, Combination ; Female ; Humans ; Letrozole/therapeutic use ; Middle Aged ; Piperazines/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Purines/adverse effects ; Pyridines/therapeutic use
Chemical Substances	Aminopyridines ; Aromatase Inhibitors ; Piperazines ; Protein Kinase Inhibitors ; Purines ; Pyridines ; Letrozole (7LKK855W8I) ; Aspartate Aminotransferases (EC 2.6.1.1) ; Alanine Transaminase (EC 2.6.1.2) ; Cyclin-Dependent Kinase 4 (EC 2.7.11.22) ; Cyclin-Dependent Kinase 6 (EC 2.7.11.22) ; palbociclib (G9ZF61LE7G) ; ribociclib (TK8ERE8P56)
Language	English
Publishing date	2019-09-08
Publishing country	United States
Document type	Case Reports
ZDB-ID	1289960-4
ISSN	1524-4741 ; 1075-122X
ISSN (online)	1524-4741
ISSN	1075-122X
DOI	10.1111/tbj.13532
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4483: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: COVID-19 in French nursing homes during the second pandemic wave: a mixed-methods cross-sectional study.

Dujmovic, Morgane / Roederer, Thomas / Frison, Severine / Melki, Carla / Lauvin, Thomas / Grellety, Emmanuel

BMJ open

2022 Volume 12, Issue 9, Page(s) e060276

Abstract: Introduction: French nursing homes were deeply affected by the first wave of the COVID-19 pandemic, with 38% of all residents infected and 5% dying. Yet, little was done to prepare these facilities for the second pandemic wave, and subsequent outbreak ... ...

Abstract	Introduction: French nursing homes were deeply affected by the first wave of the COVID-19 pandemic, with 38% of all residents infected and 5% dying. Yet, little was done to prepare these facilities for the second pandemic wave, and subsequent outbreak response strategies largely duplicated what had been done in the spring of 2020, regardless of the unique needs of the care home environment. Methods: A cross-sectional, mixed-methods study using a retrospective, quantitative data from residents of 14 nursing homes between November 2020 and mid-January 2021. Four facilities were purposively selected as qualitative study sites for additional in-person, in-depth interviews in January and February 2021. Results: The average attack rate in the 14 participating nursing facilities was 39% among staff and 61% among residents. One-fifth (20) of infected residents ultimately died from COVID-19 and its complications. Failure to thrive syndrome (FTTS) was diagnosed in 23% of COVID-19-positive residents. Those at highest risk of death were men (HR=1.78; 95% CI: 1.18 to 2.70; p=0.006), with FTTS (HR=4.04; 95% CI: 1.93 to 8.48; p<0.001) or in facilities with delayed implementation of universal FFP2 masking policies (HR=1.05; 95% CI: 1.02 to 1.07; p<0.001). The lowest mortality was found in residents of facilities with a partial (HR=0.30; 95% CI: 0.18 to 0.51; p<0.001) or full-time physician on staff (HR=0.20; 95% CI: 0.08 to 0.53; p=0.001). Significant themes emerging from qualitative analysis centred on (1) the structural, chronic neglect of nursing homes, (2) the negative effects of the top-down, bureaucratic nature of COVID-19 crisis response, and (3) the counterproductive effects of lockdowns on both residents and staff. Conclusion: Despite high resident mortality during the first pandemic wave, French nursing homes were ill-prepared for the second, with risk factors (especially staffing, lack of medical support, isolation/quarantine policy, etc) that affected case fatality and residents' and caregivers' overall well-being and mental health.
MeSH term(s)	COVID-19/epidemiology ; Communicable Disease Control ; Cross-Sectional Studies ; Female ; Humans ; Male ; Nursing Homes ; Pandemics ; Retrospective Studies
Language	English
Publishing date	2022-09-20
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2599832-8
ISSN	2044-6055 ; 2044-6055
ISSN (online)	2044-6055
ISSN	2044-6055
DOI	10.1136/bmjopen-2021-060276
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Long-Term Complete Response of an Androgen Receptor-Positive Triple-Negative Metastatic Breast Cancer to Abiraterone Acetate.

Grellety, Thomas / MacGrogan, Gaetan / Chakiba, Camille / Kind, Michele / Bonnefoi, Hervé

JCO precision oncology

2022 Volume 2

Language	English
Publishing date	2022-01-27
Publishing country	United States
Document type	Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.17.00223
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Encouraging Trends in Modern Phase 1 Oncology Trials.

Chakiba, Camille / Grellety, Thomas / Bellera, Carine / Italiano, Antoine

The New England journal of medicine

2018 Volume 378, Issue 23, Page(s) 2242–2243

MeSH term(s)	Clinical Trials, Phase I as Topic ; Humans ; Neoplasms/drug therapy ; Research Support as Topic ; Treatment Outcome
Language	English
Publishing date	2018-07-10
Publishing country	United States
Document type	Letter
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMc1803837
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data.

Rhanine, Yasmine / Bonnefoi, Hervé / Goncalves, Anthony / Debled, Marc / Le Moulec, Sylvestre / Bonichon, Nathalie / Macgrogan, Gaetan / Arnedos, Monica / Dubroca-Dehez, Bénédicte / Grellety, Thomas

Breast (Edinburgh, Scotland)

2023 Volume 73, Page(s) 103667

Abstract: Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients ... ...

Abstract	Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials.
MeSH term(s)	Humans ; Androgen Antagonists/therapeutic use ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/pathology ; Receptors, Androgen ; Nitriles/therapeutic use
Chemical Substances	Androgen Antagonists ; Receptors, Androgen ; Nitriles
Language	English
Publishing date	2023-12-22
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1143210-x
ISSN	1532-3080 ; 0960-9776
ISSN (online)	1532-3080
ISSN	0960-9776
DOI	10.1016/j.breast.2023.103667
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3620: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 588: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19 in French Nursing Homes during the Second Pandemic Wave: A Mixed-Methods Cross-Sectional Study

Dujmovic, Morgane / Roederer, Thomas / Frison, Severine / Melki, Carla / Lauvin, Thomas / Grellety-Bosviel, Emmanuel

medRxiv

Abstract: Introduction French nursing homes were deeply affected by the first wave of the COVID-19 pandemic, with 38% of all residents infected and 5% dying. Yet, little was done to prepare these facilities for the second pandemic wave, and subsequent outbreak ... ...

Abstract	Introduction French nursing homes were deeply affected by the first wave of the COVID-19 pandemic, with 38% of all residents infected and 5% dying. Yet, little was done to prepare these facilities for the second pandemic wave, and subsequent outbreak response strategies largely duplicated what had been done in the spring of 2020, regardless of the unique needs of the care home environment. Methods A cross-sectional, mixed-methods study using retrospective, quantitative data from residents of 14 nursing homes between November 2020 and mid-January 2021. Four facilities were purposively selected as qualitative study sites for additional in-person, in-depth interviews in January and February 2021. Results The average attack rate in the 14 participating nursing facilities was 39% among staff and 61% among residents. One-fifth (20) of infected residents ultimately died from COVID-19 and its complications. Failure-to-Thrive-Syndrome (FTTS) was diagnosed in 23% of COVID-positive residents. Those at highest risk of death were men (HR=1.78; IC95: 1.18 - 2.70; p=0.006) with FTTS (HR=4.04; IC95: 1.93 - 8.48; p<0.001) in facilities with delayed implementation of universal FFP2 masking policies (HR=1.05; IC95: 1.02 - 1.07; p<0.001). The lowest mortality was found in residents of facilities with a partial (HR=0.30; IC95: 0.18 - 0.51; p<0.001) or full-time physician on staff (HR=0.20; IC95: 0.08 - 0.53; p=0.001). Significant themes emerging from qualitative analysis centered on (i) the structural, chronic neglect of nursing homes, (ii) the negative effects of the top-down, bureaucratic nature of COVID-19 crisis response, and (iii) the counterproductive effects of lockdowns on both residents and staff. Conclusion Despite high resident mortality during the first pandemic wave, French nursing homes were ill-prepared for the second, with risk factors (especially staffing, lack of medical support, isolation/quarantine policy etc) that affected case fatality and residents9 and caregivers9 overall well-being and mental health.
Keywords	covid19
Language	English
Publishing date	2021-12-14
Publisher	Cold Spring Harbor Laboratory Press
Document type	Article ; Online
DOI	10.1101/2021.12.12.21267681
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Angiosarcoma associated with a Kasabach-Merritt syndrome: report of two cases treated with paclitaxel.

Grellety, Thomas / Italiano, Antoine

Future oncology (London, England)

2013 Volume 9, Issue 9, Page(s) 1397–1399

Abstract: Angiosarcomas are rare, aggressive vascular malignancies of endothelial cell differentiation. Kasabach-Merritt syndrome is a rare condition defined by the association of thrombocytopenia and consumption coagulopathy with specific vascular tumors, such as ...

Abstract	Angiosarcomas are rare, aggressive vascular malignancies of endothelial cell differentiation. Kasabach-Merritt syndrome is a rare condition defined by the association of thrombocytopenia and consumption coagulopathy with specific vascular tumors, such as tufted angioma or kaposiform hemangioendothelioma. We report here two cases of angiosarcomas complicated by a Kasabach-Merritt syndrome and their outcome after treatment with paclitaxel.
MeSH term(s)	Aged ; Aged, 80 and over ; Antineoplastic Agents, Phytogenic/therapeutic use ; Female ; Hemangiosarcoma/diagnosis ; Hemangiosarcoma/drug therapy ; Hemangiosarcoma/etiology ; Humans ; Kasabach-Merritt Syndrome/complications ; Kasabach-Merritt Syndrome/diagnosis ; Kasabach-Merritt Syndrome/therapy ; Male ; Paclitaxel/therapeutic use ; Prognosis
Chemical Substances	Antineoplastic Agents, Phytogenic ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	2013-09
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	2184533-5
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon.13.109
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Order via subito